JP2013532632A5 - - Google Patents

Download PDF

Info

Publication number
JP2013532632A5
JP2013532632A5 JP2013519762A JP2013519762A JP2013532632A5 JP 2013532632 A5 JP2013532632 A5 JP 2013532632A5 JP 2013519762 A JP2013519762 A JP 2013519762A JP 2013519762 A JP2013519762 A JP 2013519762A JP 2013532632 A5 JP2013532632 A5 JP 2013532632A5
Authority
JP
Japan
Prior art keywords
romidepsin
pharmaceutical composition
crystalline form
crystal form
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013519762A
Other languages
English (en)
Other versions
JP2013532632A (ja
JP6049614B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/043680 external-priority patent/WO2012009336A1/en
Publication of JP2013532632A publication Critical patent/JP2013532632A/ja
Publication of JP2013532632A5 publication Critical patent/JP2013532632A5/ja
Application granted granted Critical
Publication of JP6049614B2 publication Critical patent/JP6049614B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Description

本明細書に記載のように、化合物Iの結晶形態Iは、以下に図5(a)から5(y)に提供された(及び実施例7で考察された)例証的データの一部又は全てにより特性評価される。一実施態様において、化合物I形態Iについて得られたDSCサーモグラムは、〜74℃(最小)で広幅の吸熱事象を；〜100℃(最小)で吸熱を；及び、〜256.4℃(最小)で吸熱を示す(10℃/分、C)。別の実施態様において、化合物I形態Iについて得られたDSCサーモグラムは、〜88℃(最小)で広幅の吸熱事象を；〜113℃(最小)で吸熱事象を；及び、〜256℃(最小)で吸熱(10℃/分、C)を示す。一実施態様において、化合物I形態Iについて得られたTGAサーモグラムは、〜33％の重量損失を示す。別の実施態様において、化合物I形態Iについて得られたTGAサーモグラムは、〜27％の重量損失を示す。一実施態様において、下記の条件下で得られた化合物Iの形態IについてのPanalytical社X-Pert Pro MPD PW3040データが提供される：X線管：Cu(1.54059Å)、電圧：45kV；アンペア数40mA；走査範囲：1.00〜39.99°2θ；ステップサイズ：0.017°2θ；収集時間：718秒；走査速度：3.3°/分；スリット：DS：1/2°；SS：ゼロ；回転時間：1.0秒、モード：透過。一実施態様において、下記の条件下で得られた化合物I形態Iについてのデータが提供される：検出器：DTGS KBr；走査回数：512；分解能：2cm-1。

Claims (24)

  1. ロミデプシンの結晶形態C。
  2. ロミデプシンの結晶形態D。
  3. ロミデプシンの結晶形態E。
  4. ロミデプシンの結晶形態F。
  5. ロミデプシンの結晶形態H。
  6. ロミデプシンの結晶形態I。
  7. ロミデプシンの結晶形態J。
  8. ロミデプシンの結晶形態K。
  9. ロミデプシンの結晶形態L。
  10. ロミデプシンの結晶形態N。
  11. ロミデプシンの非晶質形態。
  12. 請求項1記載のロミデプシンの結晶形態Cを含有する、医薬組成物。
  13. 請求項2記載のロミデプシンの結晶形態Dを含有する、医薬組成物。
  14. 請求項3記載のロミデプシンの結晶形態Eを含有する、医薬組成物。
  15. 請求項4記載のロミデプシンの結晶形態Fを含有する、医薬組成物。
  16. 請求項5記載のロミデプシンの結晶形態Hを含有する、医薬組成物。
  17. 請求項6記載のロミデプシンの結晶形態Iを含有する、医薬組成物。
  18. 請求項7記載のロミデプシンの結晶形態Jを含有する、医薬組成物。
  19. 請求項8記載のロミデプシンの結晶形態Kを含有する、医薬組成物。
  20. 請求項9記載のロミデプシンの結晶形態Lを含有する、医薬組成物。
  21. 請求項10記載のロミデプシンの結晶形態Nを含有する、医薬組成物。
  22. 血液疾患の治療用医薬の製造のための、請求項1〜11のいずれか一項記載のロミデプシンの使用。
  23. 血液疾患の治療用医薬の製造のための、請求項12〜21のいずれか一項記載の医薬組成物の使用。
  24. 前記血液疾患が、末梢T細胞リンパ腫(PTCL)又は皮膚T細胞リンパ腫(CTCL)である、請求項22又は23記載の使用。
JP2013519762A 2010-07-12 2011-07-12 ロミデプシン固体形態及びそれらの使用 Active JP6049614B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36352210P 2010-07-12 2010-07-12
US61/363,522 2010-07-12
PCT/US2011/043680 WO2012009336A1 (en) 2010-07-12 2011-07-12 Romidepsin solid forms and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016147920A Division JP6490632B2 (ja) 2010-07-12 2016-07-28 ロミデプシン固体形態及びそれらの使用

Publications (3)

Publication Number Publication Date
JP2013532632A JP2013532632A (ja) 2013-08-19
JP2013532632A5 true JP2013532632A5 (ja) 2014-08-28
JP6049614B2 JP6049614B2 (ja) 2016-12-21

Family

ID=44514993

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013519762A Active JP6049614B2 (ja) 2010-07-12 2011-07-12 ロミデプシン固体形態及びそれらの使用
JP2016147920A Active JP6490632B2 (ja) 2010-07-12 2016-07-28 ロミデプシン固体形態及びそれらの使用
JP2018227150A Pending JP2019052177A (ja) 2010-07-12 2018-12-04 ロミデプシン固体形態及びそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016147920A Active JP6490632B2 (ja) 2010-07-12 2016-07-28 ロミデプシン固体形態及びそれらの使用
JP2018227150A Pending JP2019052177A (ja) 2010-07-12 2018-12-04 ロミデプシン固体形態及びそれらの使用

Country Status (16)

Country Link
US (5) US20120190817A2 (ja)
EP (1) EP2593123B1 (ja)
JP (3) JP6049614B2 (ja)
KR (1) KR20130092557A (ja)
CN (1) CN103108648A (ja)
AU (1) AU2011279303B2 (ja)
BR (1) BR112013000673A2 (ja)
CA (1) CA2804795A1 (ja)
ES (1) ES2755909T3 (ja)
MX (1) MX342913B (ja)
MY (1) MY185130A (ja)
NZ (2) NZ605526A (ja)
RU (2) RU2016149485A (ja)
SG (2) SG10201505475XA (ja)
UA (1) UA114074C2 (ja)
WO (1) WO2012009336A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2450049A1 (en) * 2006-12-29 2012-05-09 Gloucester Pharmaceuticals, Inc. Romidepsin-based treatments for cancer
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
US20130184225A1 (en) 2012-01-12 2013-07-18 Lianfeng Huang Romidepsin formulations and uses thereof
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
CN103877010B (zh) * 2012-12-21 2018-06-01 正大天晴药业集团股份有限公司 一种罗米地辛溶液的制备方法
WO2014102731A1 (en) * 2012-12-31 2014-07-03 Leiutis Pharmaceuticals Pvt. Ltd Novel pharmaceutical compositions of romidepsin
ITMI20131856A1 (it) * 2013-11-08 2015-05-09 Gnosis Spa Processo per la preparazione di differenti forme cristalline del s-acetil glutatione e loro utilizzi in formulazioni farmaceutiche e nutraceutiche
CN103861084A (zh) * 2014-02-12 2014-06-18 新乡医学院 Romidepsin在治疗帕金森病中的应用
CN104262456B (zh) * 2014-09-11 2018-01-09 浙江海正药业股份有限公司 一种罗米地辛的新晶型及其制备方法和用途
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP4049665A1 (en) 2016-03-15 2022-08-31 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
CN105801667B (zh) * 2016-03-22 2019-04-09 浙江海正药业股份有限公司 一种制备无定型罗米地辛的方法
AU2017363250A1 (en) * 2016-11-22 2019-06-06 Alkalidx, Inc. Therapies for the treatment of Lidocaine-Ineffective and hypokalemic conditions
CN109796521B (zh) * 2017-11-17 2022-04-19 上海医药工业研究院 一种罗米地辛醋酸盐晶型及其制备方法
CN111187337B (zh) * 2018-11-15 2023-01-24 上海医药工业研究院 罗米地辛一异丙醇溶剂合物及其晶型、制备方法和应用
WO2020139453A2 (en) * 2018-12-24 2020-07-02 Marrone Bio Innovations, Inc. A method for increasing romidepsin production from fermentation broth
CN113813366A (zh) * 2020-06-18 2021-12-21 中国科学院深圳先进技术研究院 罗米地辛在制备预防和治疗抗新冠肺炎新型冠状病毒的药物中的应用
WO2021253338A1 (zh) * 2020-06-18 2021-12-23 中国科学院深圳先进技术研究院 罗米地辛在预防和治疗冠状病毒相关疾病中的应用

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
JPH0764872A (ja) 1993-08-26 1995-03-10 Fujitsu Ten Ltd データ記憶制御装置
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US5776905A (en) 1996-08-08 1998-07-07 The Board Of Trustees Of The Leland Stamford Junior University Apoptotic regression of intimal vascular lesions
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
WO1999011659A1 (fr) 1997-09-02 1999-03-11 Japan Energy Corporation Derives tetrapeptides cycliques et leur utilisation medicinale
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
EP1231919B1 (en) 1999-09-08 2015-09-30 Sloan-Kettering Institute For Cancer Research Derivatives of 1-amino-1-(hetero)arylaminocarbonyl-6-hydroxyaminocarbonylhexane useful in the treatment of tumors
EP1438966B1 (en) 1999-12-08 2007-02-14 Cyclacel Pharmaceuticals, Inc. Use of depsipeptide and congeners thereof as immunosuppressants for treating an infectious disease, an autoimmune disease, allergic reactions or a hyperproliferative skin disease.
US6828302B1 (en) 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
CA2317003A1 (en) 2000-02-28 2001-08-28 Hidenori Nakajima Gene expression potentiator
JP2001348340A (ja) 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
ES2321584T3 (es) 2000-07-17 2009-06-09 Astellas Pharma Inc. Fk228 reducido y su uso.
AU2001285042A1 (en) * 2000-08-18 2002-03-04 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
US7396665B2 (en) * 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
JP2005507231A (ja) 2001-01-10 2005-03-17 アメリカ合衆国 甲状腺新生物の診断および治療におけるヒストン脱アセチル酵素阻害剤
EP1353693B1 (en) * 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
US7219016B2 (en) 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
ES2310213T3 (es) 2001-05-02 2009-01-01 The Regents Of The University Of California Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa.
AU2002305769B2 (en) 2001-05-30 2007-07-19 Georgetown University Small molecule antagonists of Bcl2 family proteins
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
MXPA04001612A (es) 2001-08-21 2004-07-08 Fujisawa Pharmaceutical Co Uso medicinal de inhibidor de la histona desacetilasa y metodo para evaluar el efecto antitumoral del mismo.
US20040259772A1 (en) 2001-08-24 2004-12-23 Antonio Fojo Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
US20050123896A1 (en) 2001-10-25 2005-06-09 Benz Christopher C. Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby
US7354928B2 (en) 2001-11-01 2008-04-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at Bcl-2
WO2003053468A1 (en) 2001-12-21 2003-07-03 Universite Libre De Bruxelles Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
US20030134423A1 (en) 2002-01-04 2003-07-17 Chu Yong Liang Compounds for delivering substances into cells
EP1482962A4 (en) 2002-02-15 2009-12-23 Sloan Kettering Inst Cancer METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
WO2003070754A1 (fr) 2002-02-20 2003-08-28 Minoru Yoshida Inhibiteurs d'histone desacetylase et procede de production de ces inhibiteurs
EP2266552A3 (en) 2002-03-04 2011-03-02 Merck HDAC Research, LLC Methods of inducing terminal differentiation
WO2003083067A2 (en) 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
EP1492596A1 (en) 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
AU2003226408B2 (en) 2002-04-15 2007-06-14 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US6809118B2 (en) 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US20040002447A1 (en) 2002-06-04 2004-01-01 Regents Of The University Of California Induction of insulin expression
WO2004009771A2 (en) 2002-07-24 2004-01-29 Advanced Stent Technologies, Inc. Stents capable of controllably releasing histone deacetylase inhibitors
ATE465757T1 (de) 2002-08-20 2010-05-15 Astellas Pharma Inc Hemmer des abbaus der extrazellulären matrix von arthrodia-knorpel
BR0314112A (pt) 2002-09-13 2005-07-12 Univ Virginia Commonwealth Combinação de a) n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e b) um inibidor de desacetilase de histona para o tratamento de leucemia
SE0300098D0 (sv) 2003-01-15 2003-01-15 Forskarpatent I Syd Ab Use of cyclin D1 inhibitors
US20050222013A1 (en) 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
WO2004074478A1 (ja) 2003-02-19 2004-09-02 Astellas Pharma Inc. ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
WO2004096289A1 (ja) 2003-04-25 2004-11-11 Fujisawa Pharmaceutical Co 遺伝子導入効率増強剤
US20040213826A1 (en) 2003-04-28 2004-10-28 Marx Steven O. Medical devices and methods for inhibiting proliferation of smooth muscle cells
EP1491188A1 (en) 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
PT2238982E (pt) 2003-06-27 2013-01-22 Astellas Pharma Inc Agente terapêutico para o sarcoma de tecidos moles
JP4777887B2 (ja) 2003-07-23 2011-09-21 バイエル、ファーマシューテイカルズ、コーポレイション 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素
DK1663194T3 (da) 2003-08-26 2010-07-19 Merck Hdac Res Llc Anvendelse af SAHA til behandling af mesotheliom
CN101856348A (zh) 2003-08-29 2010-10-13 斯隆-凯特林癌症研究所 联合治疗癌症的方法
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
JP2007505914A (ja) 2003-09-18 2007-03-15 コンビナトアールエックス インコーポレーティッド 新生物の治療のための薬物の併用方法
DK2263694T3 (da) * 2003-09-25 2013-08-26 Astellas Pharma Inc Antitumormiddel omfattende histon-deacetylase-inhibitoren FK228 og topoisomerase-II-inhibitoren doxorubicin
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
EP1689446B1 (de) 2003-11-14 2015-01-07 Per Sonne Holm Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung
WO2005053609A2 (en) 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
EP1713460A2 (en) 2003-12-10 2006-10-25 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
US20050187148A1 (en) 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
ATE437370T1 (de) 2004-02-27 2009-08-15 Us Gov Health & Human Serv Pharmakodynamische tests mit durchflusszytometrie
GB0405349D0 (en) 2004-03-10 2004-04-21 Univ Birmingham Cancer therapy and medicaments therefor
ITMI20040876A1 (it) 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
ATE399539T1 (de) 2004-04-30 2008-07-15 Topotarget Germany Ag Histondeacetylase-inhibitor enthaltende formulierung zur zweiphasigen freisetzung
WO2005115149A2 (en) 2004-05-20 2005-12-08 Dow Agrosciences Llc Insectidal activity of a cyclic peptide
WO2005117930A2 (en) 2004-06-04 2005-12-15 Sloan-Kettering Institute For Cancer Research Use of thioredoxin measurements for diagnostics and treatments
US7470722B2 (en) 2004-06-10 2008-12-30 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20060018921A1 (en) 2004-07-16 2006-01-26 Baylor College Of Medicine Histone deacetylase inhibitors and cognitive applications
WO2006027346A2 (en) 2004-09-06 2006-03-16 Altana Pharma Ag Novel pyrazolopyrimidines
AU2005307814A1 (en) 2004-11-17 2006-05-26 The University Of Chicago Histone deacetylase inhibitors and methods of use
WO2006060382A2 (en) 2004-11-30 2006-06-08 Trustees Of The University Of Pennsylvania Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
WO2006060429A2 (en) 2004-12-03 2006-06-08 Novartis Ag Identification of variants in histone deacetylase 1 (hdac1) to predict drug response
US20060128660A1 (en) 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
US7943568B2 (en) 2005-09-30 2011-05-17 The Ohio State University Research Foundation Antitumor agents
WO2007049736A1 (ja) * 2005-10-28 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. 濃縮晶析装置および方法
WO2007058896A2 (en) 2005-11-10 2007-05-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
WO2007061939A2 (en) 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
WO2007145704A2 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
US7857804B2 (en) 2006-09-01 2010-12-28 Mccaffrey Timothy A Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders
EP2450049A1 (en) 2006-12-29 2012-05-09 Gloucester Pharmaceuticals, Inc. Romidepsin-based treatments for cancer
EP2102230A2 (en) 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Purifiction of romidepsin
CN102276689A (zh) 2011-05-09 2011-12-14 中国药科大学 组蛋白去乙酰化酶抑制剂fk228的化学合成方法及其应用

Similar Documents

Publication Publication Date Title
JP2013532632A5 (ja)
JP2020511467A5 (ja)
JP2016538314A5 (ja)
JP2019528276A5 (ja)
JP2011522827A5 (ja)
JP2010539237A5 (ja)
RU2599785C3 (ru) Кристаллические формы 5-хлор-n2-(2-изопропокси-5-метил-4-пиперидин-4-ил-фенил)-n4-[2-(пропан-2-сульфонил)-фенил]-пиримидин-2,4-диамина
JP2016503010A5 (ja)
CY1119326T1 (el) Φαινυλο-3-αζα-δικυκλο[3.1.0]εξ-3-υλο-μεθανονες και η χρηση αυτων ως φαρμακο
JP2018531280A5 (ja)
JP2007532560A5 (ja)
CA2688708A1 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
JP2020536893A5 (ja)
JP2016528179A5 (ja)
FI2744810T4 (fi) Tenofoviirialafenamidihemifumaraatti
FI3057962T3 (fi) Hydrokloridisuolamuoto ezh2-estoon
JP2015503610A5 (ja)
JP2019519587A5 (ja)
JP2012502111A5 (ja)
JP2010132668A5 (ja)
JP2014520163A5 (ja)
ES2769049T1 (es) Forma cristalina de tetraclorhidrato de trietilentetramina y su uso farmacéutico
JP2015520770A5 (ja)
JP2013544244A5 (ja)
JP2012509281A5 (ja)